vs
BillionToOne, Inc.（BLLN）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
BillionToOne, Inc.的季度营收约是READING INTERNATIONAL INC的1.7倍（$83.5M vs $50.3M），BillionToOne, Inc.净利率更高（6.8% vs -5.1%，领先11.9%），BillionToOne, Inc.同比增速更快（117.4% vs -14.2%），BillionToOne, Inc.自由现金流更多（$6.5M vs $4.1M）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
BLLN vs RDI — 直观对比
营收规模更大
BLLN
是对方的1.7倍
$50.3M
营收增速更快
BLLN
高出131.6%
-14.2%
净利率更高
BLLN
高出11.9%
-5.1%
自由现金流更多
BLLN
多$2.3M
$4.1M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $50.3M |
| 净利润 | $5.7M | $-2.6M |
| 毛利率 | 69.9% | — |
| 营业利润率 | 11.5% | -1.9% |
| 净利率 | 6.8% | -5.1% |
| 营收同比 | 117.4% | -14.2% |
| 净利润同比 | 138.3% | -14.5% |
| 每股收益（稀释后） | $0.10 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNRDI
| Q4 25 | — | $50.3M | ||
| Q3 25 | $83.5M | $52.2M | ||
| Q2 25 | — | $60.4M | ||
| Q1 25 | — | $40.2M | ||
| Q4 24 | — | $58.6M | ||
| Q3 24 | $38.4M | $60.1M | ||
| Q2 24 | — | $46.8M | ||
| Q1 24 | — | $45.1M |
净利润BLLNRDI
| Q4 25 | — | $-2.6M | ||
| Q3 25 | $5.7M | $-4.2M | ||
| Q2 25 | — | $-2.7M | ||
| Q1 25 | — | $-4.8M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | $-14.9M | $-7.0M | ||
| Q2 24 | — | $-12.8M | ||
| Q1 24 | — | $-13.2M |
毛利率BLLNRDI
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率BLLNRDI
| Q4 25 | — | -1.9% | ||
| Q3 25 | 11.5% | -0.6% | ||
| Q2 25 | — | 4.8% | ||
| Q1 25 | — | -17.2% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | -32.9% | -0.6% | ||
| Q2 24 | — | -16.4% | ||
| Q1 24 | — | -16.7% |
净利率BLLNRDI
| Q4 25 | — | -5.1% | ||
| Q3 25 | 6.8% | -8.0% | ||
| Q2 25 | — | -4.4% | ||
| Q1 25 | — | -11.8% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | -38.8% | -11.7% | ||
| Q2 24 | — | -27.4% | ||
| Q1 24 | — | -29.4% |
每股收益（稀释后）BLLNRDI
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $0.10 | $-0.18 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | $-1.47 | $-0.31 | ||
| Q2 24 | — | $-0.57 | ||
| Q1 24 | — | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | $10.5M |
| 总债务越低越好 | $55.0M | $185.1M |
| 股东权益账面价值 | $-239.5M | $-18.2M |
| 总资产 | $327.5M | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLLNRDI
| Q4 25 | — | $10.5M | ||
| Q3 25 | $195.2M | $8.1M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $5.9M | ||
| Q4 24 | — | $12.4M | ||
| Q3 24 | — | $10.1M | ||
| Q2 24 | — | $9.3M | ||
| Q1 24 | — | $7.5M |
总债务BLLNRDI
| Q4 25 | — | $185.1M | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BLLNRDI
| Q4 25 | — | $-18.2M | ||
| Q3 25 | $-239.5M | $-12.1M | ||
| Q2 25 | — | $-7.7M | ||
| Q1 25 | — | $-8.1M | ||
| Q4 24 | — | $-4.4M | ||
| Q3 24 | $-242.9M | $1.6M | ||
| Q2 24 | — | $6.5M | ||
| Q1 24 | — | $18.0M |
总资产BLLNRDI
| Q4 25 | — | $434.9M | ||
| Q3 25 | $327.5M | $435.2M | ||
| Q2 25 | — | $438.1M | ||
| Q1 25 | — | $441.0M | ||
| Q4 24 | — | $471.0M | ||
| Q3 24 | — | $495.7M | ||
| Q2 24 | — | $494.9M | ||
| Q1 24 | — | $494.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | $4.1M |
| 自由现金流率自由现金流/营收 | 7.7% | 8.2% |
| 资本支出强度资本支出/营收 | 8.8% | 0.3% |
| 现金转化率经营现金流/净利润 | 2.42× | — |
| 过去12个月自由现金流最近4个季度 | — | $-2.9M |
8季度趋势，按日历期对齐
经营现金流BLLNRDI
| Q4 25 | — | $4.3M | ||
| Q3 25 | $13.8M | $295.0K | ||
| Q2 25 | — | $1.6M | ||
| Q1 25 | — | $-7.7M | ||
| Q4 24 | — | $8.0M | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $-10.4M | ||
| Q1 24 | — | $-2.8M |
自由现金流BLLNRDI
| Q4 25 | — | $4.1M | ||
| Q3 25 | $6.5M | $-246.0K | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $-8.0M | ||
| Q4 24 | — | $7.0M | ||
| Q3 24 | — | $-1.1M | ||
| Q2 24 | — | $-10.6M | ||
| Q1 24 | — | $-4.7M |
自由现金流率BLLNRDI
| Q4 25 | — | 8.2% | ||
| Q3 25 | 7.7% | -0.5% | ||
| Q2 25 | — | 1.9% | ||
| Q1 25 | — | -19.8% | ||
| Q4 24 | — | 12.0% | ||
| Q3 24 | — | -1.8% | ||
| Q2 24 | — | -22.7% | ||
| Q1 24 | — | -10.4% |
资本支出强度BLLNRDI
| Q4 25 | — | 0.3% | ||
| Q3 25 | 8.8% | 1.0% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 4.3% |
现金转化率BLLNRDI
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
